Full-Time

Associate Director

Digital Quality Management Systems, Change Management and Digital Adoption

Posted on 5/9/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$139.9k - $189.9k/yr

+ Bonus + Equity Grants

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
Veeva
ServiceNow
Word/Pages/Docs
JIRA
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree and 8+ years of Life Science, Engineering, Information Systems, or related experience in a regulated life sciences environment required
  • Or Master’s degree and 6+ years of Life Science, Engineering, Information Systems, or related experience in a regulated life sciences environment preferred
  • 7+ years of related experience in Quality Systems, Change Management and Digital Adoption
  • Strong PC literacy required; MS Office skills (Outlook, Word, Excel, PowerPoint, Teams)
  • Proficient in digital adoption tools (e.g., WalkMe) for creating guided workflows and just-in-time training
  • Expertise in digital quality systems (e.g. Veeva Quality Vault, Valgenesis Validation Lifecycle Suite, Compliance Wire, etc..)
  • Proficient in collaborative work management tools such as Smartsheet, JIRA, ServiceNow, etc.
  • Familiarity with Artificial Intelligence (AI) tools
  • Experience leveraging AI for process optimization and predictive insights
  • Workflow automation and configuration skills
  • Travel: Up to 15%
Responsibilities
  • Develop and implement effective communication strategies to inform and engage users before, during, and after the adoption of new digital quality tools and processes
  • Collaborate with key stakeholders to understand their needs, expectations, and concerns regarding digital adoption and changes
  • Build and maintain strong relationships with various departments to facilitate open communication and support for initiatives
  • Create informative materials such as newsletters, presentations, and other communication assets
  • Design and deliver comprehensive training programs tailored to different user groups based on their roles and levels of digital proficiency
  • Prepare user guides, FAQs, and other relevant documentation to support ongoing learning and development
  • Monitor the progress of digital tool adoption and identify potential barriers to usage
  • Conduct surveys and feedback sessions to assess user satisfaction and engagement
  • Identify and mitigate risks associated with the change process
  • Develop risk assessment plans and implement risk mitigation strategies
  • Create dashboards, KPIs, and metrics to evaluate adoption effectiveness and overall success of digital initiatives
  • Provide regular reports to management highlighting progress, challenges, and recommendations for improvement
  • Maintain thorough documentation of change management processes, methodologies, and lessons learned to ensure consistency and efficiency in future initiatives
  • Gather and analyze feedback from users to identify opportunities for continuous improvement in systems training and adoption strategies
  • Stay current with industry best practices and emerging trends in digital adoption and change management
  • Support the optimization of digital adoption tools like WalkMe, ensuring they are effectively utilized to enhance user experience
  • Create engaging content for digital adoption tools, including step-by-step guides, in-app tutorials, and interactive training modules
  • Serve as the Business Process Owner for AI capabilities within Global Quality, driving cross‑functional alignment on requirements, governance, and standards for AI‑enabled workflows
  • Define, maintain, and continuously improve AI‑enabled business processes, including governance models, RACI, decision workflows, and process controls related to AI use in Quality Systems
  • Lead the evaluation, prioritization, and intake of AI opportunities within Global Quality, maintaining an AI capability roadmap that supports efficiency, automation, and predictive insights
  • Represent Global Quality in cross‑functional AI governance bodies, ensuring Quality requirements are embedded in enterprise AI frameworks and decision‑making

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA sales reached $3.9B in 2025, growing 49% year-over-year.
  • TEVIMBRA plus ZIIHERA shows extended survival versus trastuzumab in gastric cancer.
  • Three solid tumor programs advancing to late-stage trials with 60+ abstracts.

What critics are saying

  • BRUKINSA represents 73% of revenue; market share loss to competitors accelerates decline.
  • BEQALZI conditional approval requires CELESTIAL-RRMCL Phase 3 trial success by 2027.
  • Generic ibrutinib competition by 2027-2028 forces BRUKINSA price cuts or market share loss.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL.
  • BEQALZI is first BCL2 inhibitor approved for relapsed/refractory mantle cell lymphoma.
  • Global GMP manufacturing network enables cost-efficient drug development across 45+ countries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...